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Whereas previous investigations have shown that
pharmacologic addition of gangliosides inhibits kera-
tinocyte proliferation by downregulating epidermal
growth factor receptor phosphorylation, the underly-
ing biochemical basis and physiologic relevance are
unknown. Using Scatchard and displacement plots,
we have shown that supplemental puri®ed ganglio-
sides decrease the binding of 125I-labeled epidermal
growth factor to keratinocyte-derived SCC12 cells.
Conversely, SCC12 cells transfected with sialidase
and thus depleted of gangliosides show increased
ligand binding to the epidermal growth factor recep-
tor, which is consistent with their increased prolif-
eration in response to epidermal growth factor and
transforming growth factor-a, and increased phos-
phorylation of the epidermal growth factor receptor,
and downstream signal transduction pathway com-
ponents. The mechanism of the altered binding
appears to involve primarily decreased numbers of
available receptors within the intact membrane, but
not altered receptor protein expression. These studies
provide evidence that the effect of gangliosides on
keratinocyte proliferation results, at least in part,
from the direct binding of ganglioside to the recep-
tor and disruption of the receptor±ligand interaction.
Manipulation of membrane ganglioside content may
be a powerful new means to alter epidermal growth
factor receptor-dependent cell proliferation. Key
words: epidermis/glycosphingolipid/glycosylation/sialidase.
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E
pidermal growth factor receptor (EGF-R), a transmem-
brane tyrosine kinase, can be activated by binding to its
ligands, particularly epidermal growth factor (EGF),
transforming growth factor-a (TGF-a), heparin-bind-
ing EGF-like growth factor, and amphiregulin (Brach-
mann et al, 1989; Wong et al, 1989). Receptor binding requires a
50 amino acid core sequence with a characteristically spaced six
cysteine pattern that is found in all members of the EGF/TGF-a
family (Derynck, 1992). After binding with its ligand, the receptor
dimerizes, undergoes autophosphorylation, and subsequently
induces signaling transduction cascades, such as the phosphatidy-
linositol-3 kinase pathway (Vanhaesebroeck et al, 1997) and
mitogen-activated protein (MAP) kinases, leading to a mitogenic
response and increasing cell proliferation (Schlessinger and Ullrich,
1992). Overexpression of EGF-R has been described for many
human tumors, including breast, lung, colon, prostate, brain, head
and neck, renal, and ovarian carcinomas, and the increased level of
receptors tends to correlate with a poorer clinical prognosis (for
reviews, Gullick, 1991; Salomon et al, 1995; Modjtahedi et al,
1998). Consistently, intraperitoneal injection of an anti-EGF-R
monoclonal antibody without concomitant chemotherapy is able to
eradicate completely both the development of epidermoid
carcinomas and fully established carcinomas in mice with human
tumor xenografts (Yang et al, 1999). These observations suggest that
an increased understanding of the factors that in¯uence EGF-R
function may lead to novel interventions for patients with cancer.
Keratinocytes and keratinocyte-derived cells are prototypes of
cells that require EGF-R activation for proliferation (Green et al,
1983; Dong et al, 1991). Previous studies have shown that the
pharmacologic addition of ganglioside GM3 to cultured keratino-
cytes, the major ganglioside of keratinocytes and keratinocyte-
derived cell lines (Paller et al, 1992), results in an increased
membrane concentration of GM3 (Paller et al, 1993), inhibits
keratinocyte proliferation (Paller et al, 1993), and downregulates
EGF-R phosphorylation.1 These observations are consistent with
the demonstration of decreased epidermal binding of anti-GM3
antibody to keratinocytes in skin biopsy sections of patients with
hyperproliferative skin disorders, including psoriasis, squamous cell
carcinoma, and congenital ichthyosiform erythroderma (Paller et al,
1989). GM3 is a monosialylated ganglioside that serves as the
precursor for gangliosides in both the ``a'' pathway (GM2, GM,
GD1a) and ``b'' pathway (GD3, GD2, GT1b), synthesized through
the addition of sialic acid(s) and other carbohydrate groups by
glycosyltransferases (Van Echten and Sandhoff, 1993). Only GM3
and gangliosides of the ``b'' synthetic pathway of ganglioside
synthesis, including GD3 and GT1b, are able to inhibit
keratinocyte proliferation in vitro, whereas gangliosides of the ``a''
synthetic pathway, including GM2 and GD1a, do not affect cell
proliferation (Paller et al, 1993).
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The biochemical basis for the downregulatory effect of ganglio-
sides on phosphorylation of EGF-R is unclear. Previous studies
have provided evidence that exogenously added gangliosides affect
the binding of other growth factors to their receptors, including
®broblast growth factor in BHK hamster ®broblasts (Bremer and
Hakomori, 1982) and platelet-derived growth factor-BB in vascular
smooth muscle cells (Sachinidis et al, 1996); a ganglioside-induced
alteration in binding of EGF-R to its ligand, however, was not
observed in A431 cells, and a postbinding receptor activation has
been assumed. We have investigated the possibility that gangliosides
change the ability of EGF or TGF-a to bind to the EGF-R using a
keratinocyte-derived cell line, SCC12, that responds to gangliosides
in a manner that resembles that of normal cultured keratinocytes
(Paller et al, 1993; Sung et al, 1998). Using both the pharmacologic
addition of gangliosides as a means to increase ganglioside
membrane content and stable transfection into SCC12 cells of a
sialidase cDNA that metabolizes gangliosides as a means to deplete
membrane gangliosides, we have shown that gangliosides affect the
binding of EGF and TGF-a to the EGF-R primarily through
modulating the number of receptors available for binding.
MATERIALS AND METHODS
Reagents The pcDNA3 expression vector was purchased from
Invitrogen (San Diego, CA). Sialidase cDNA was a generous gift from
Dr Thomas Warner (Genentech, CA). LipofectAMINE reagent,
Dulbecco's modi®ed Eagle's medium/Nutrient Mixture F-12, fetal
bovine serum (FBS), Geneticin (G418), and restriction enzymes BamHI
and XbaI were purchased from Life Technologies (Grand Island, NY).
Gangliosides GM2 and GM3 were obtained from Calbiochem (La Jolla,
CA). Plasmid preparation and RNA isolation kits were bought from
Qiagen (Valencia, CA), and antibodies against phosphotyrosine (PY20),
EGF-R activated form, EGF-R, PTP1D, PI3 kinase, MAP kinase, protein
A-agarose, and horseradish-linked peroxidase from Transduction
Laboratories (Lexington, KY). [g-32P]adenosine triphosphate ([g-
32P]ATP), 125I-EGF (speci®c activity ranged from 121 to 140 Ci per
mmol) and the enhanced chemiluminescence reagent kit were purchased
from Amersham Pharmacia (Piscataway, NJ). EGF, digoxigenin (DIG)-
labeled peanut agglutinin, DIG-labeled Maackia amurensis agglutinin
(MAA), DIG-labeled Sambucus nigra agglutinin (SNA), and DIG-High
Prime DNA Labeling and Detection Starter Kit II were bought from
Roche (Indianapolis, IN). C-18 Column and precoated silica gel TCL glass
plate were purchased from Merck (Gibbstown, NJ). The human squamous
cell carcinoma cell line SCC12F2 (SCC12), derived from a facial squamous
cell carcinoma, was a generous gift from Dr James Rheinwald (Boston,
MA). X-Omat ®lm was obtained from Kodak (Rochester, NY),
polyvinylidene di¯uoride membrane from Millipore (Bedford, MA), and
nitrocellulose membrane from BioRad (Hercules, CA). All other reagents
were purchased from Sigma (St Louis, MO).
Cell culture All cells were grown in complete medium of DMEM/F12
(1:1) supplemented with 10% heat-inactivated FBS without antibiotics
under a 5% CO2 atmosphere at 37°C.
Binding of 125I-EGF Binding of labeled EGF to whole cells was
assessed using modi®cations of previously described methods for Scatchard
analysis (Bowen-Pope et al, 1983; Collins et al, 1983; Bremer et al, 1984)
and speci®c displacement tests (Wang et al, 1999). In brief, three parallel sets
of 104 SCC12 cells were grown in 96-well Multiscreen ®lter plates
(Millipore) in complete medium for 12±14 h. The cells were washed and
incubated in medium with 2% FBS with or without 50 mM gangliosides
GM1, GM2, GM3, GD3, or GT1b. After an additional 48 h, one set of
cells was washed, and incubated at 4°C for 4 h with 0.1 nM to 25.6 nM
125I-labeled human recombinant EGF in phosphate-buffered saline
supplemented with 25 mM HEPES pH 7.4 and 0.1% bovine serum
albumin without cold EGF to determine total binding. To determine
nonspeci®c binding, a second set of cells were incubated for 4 h with the
same concentrations of labeled EGF, but with additional cold EGF totaling
1 mM EGF per well. After washing, the membranes in these two sets were
air dried, transferred to scintillation ¯uid, and total cell-associated
radioactivity determined by a Beckman LS 6000 SC machine. Speci®c
binding was calculated as the difference between bound cpm in the absence
or presence of excess unlabeled EGF, with nonspeci®c binding < 2% of the
total cpm added to each well. The third set of cells was grown for 48 h with
or without ganglioside, subsequently trypsinized, and the cell number
counted in a hemacytometer. Data were analyzed using a Scatchard plot
(Scatchard, 1949). Displacement assays were performed as described above
with and without gangliosides, except that all cells were incubated with
12 nM 125I-EGF (saturating concentration) and increasing concentrations of
cold EGF up to 1 mM. For displacement assays with the six sialidase-
transfected SCC12 cells and controls, 4 3 104 cells were seeded initially,
and cells were not exposed to exogenous ganglioside. All binding assays
were performed in triplicate.
Sialidase cDNA transfection and selection Using lipofectAMINE
reagent, sialidase cDNA was transfected into SCC12 cells. Putative
transfectants were selected by antibiotic resistance to 500 mg per ml G418
and then subjected to limiting dilution to ensure clonality. Positive
transfectants were further selected by measurements of sialidase activity and
by northern assays of sialidase mRNA expression, as described in A-431
cells (Meuillet et al, 1999).
Effect of sialidase overexpression on membrane ganglioside
content Gangliosides were extracted from precon¯uent cells in a 1:1
(vol/vol) ratio of chloroform/methanol (Folch-Pi et al, 1957). After
centrifugation, the upper phase containing the ganglioside was evaporated
under a stream of nitrogen, and the resultant crude ganglioside powder was
desalted with a C-18 column. Puri®ed gangliosides were dissolved in
chloroform/methanol solvent, applied to a silica-coated glass plate, and
separated by thin layer chromatography in chloroform/methanol/0.2%
CaCl2 solution (55/45/10). Sialylated glycosphingolipids (gangliosides)
were detected by a spray of 0.2% resorcinol, 75% H2SO4, 250 mM CuSO4,
and heating at 120°C. A mixture of individual gangliosides served as a lane
of standards. Gangliosides from each clone and parental cells were extracted
four times and assessed.
Speci®city of sialidase activity for gangliosides The glycosylation
state of glycoproteins and speci®cally EGF-R was determined by western
blot analysis and lectin binding according to manufacturer's instructions
(Roche Molecular Biochemicals, Indianapolis, IN). Cell membrane
proteins were extracted by treatment with lysis buffer (25 mM Tris±HCl
pH 7.5, 0.1% Triton X-100, 125 mM NaCl, and 1 mM Na3VO4) and the
cell debris was removed by centrifugation. Fifty to 100 mg protein per lane
of parental SCC12 cells, three different mock pcDNA clones, and six stable
sialidase-transfected clones were loaded on an 8% sodium dodecyl sulfate±
polyacrylamide gel electrophoresis (SDS±PAGE) minigel. The protein was
then transferred to nitrocellulose membrane, and membranes were probed
with 5±10 mg per ml DIG-labeled MAA to detect a2,3-sialylation, 1 mg
per ml DIG-labeled SNA to detect a2,6-sialylation, or 10±40 mg per ml
DIG-labeled peanut agglutinin to detect the desialylated core protein.
Binding to the lectin was detected by incubation with 0.75 units per ml
sheep anti-DIG Fab fragments, conjugated with alkaline phosphatase, and
staining the membrane with 4-nitroblue tetrazolium chloride/X-phosphate
solution. Lectin analysis was also performed as described above using
immunoprecipitated EGF-R from parental cells, the mock cell clones and
six sialidase-positive clones. EGF-R was immunoprecipitated by mixing
anti-EGF-R monoclonal antibody (5 mg per clone) with total cell protein
(500 mg), and subsequently precipitating with protein A-agarose beads as
per manufacturer's instructions. Studies with immunoprecipitated EGF-R
were repeated three times. Desialylated fetuin (61 kDa), fetuin (68 kDa),
and transferrin (80 kDa) were applied as positive controls for lectin staining
for peanut agglutinin, MAA, and SNA, respectively.
Cell proliferation assays Cells were seeded in 12-well plates at 104 cells
per well, trypsinized and counted daily for 8 d. To test the effect of addition
of EGF or TGF-a, cells were grown for 12 h in serum-containing medium,
starved overnight of both serum and growth factors, and then treated with
10 nM EGF or 12 nM TGF-a. Medium with the EGF or TGF-a was
replenished every 3 d. To test the effect of speci®c inhibitor of sialidase
activity, cells were instead treated with or without 100 mM 2,3-dehydro-2-
deoxy-N-acetylenuraminic acid for 18 h. All proliferation assays were run
in quadruplicate, and the studies were performed at least four times.
EGF-R expression and phosphorylation To determine the effect of
depletion of ganglioside on the tyrosine phosphorylation of EGF-R,
sialidase-transfected SCC12 cells in six well plates were serum starved for
18 h. Cells were then either treated with 10 nM EGF for 5±30 min, or with
10±100 nM EGF for 10 min. The cells were boiled in lysis buffer (1% SDS,
10 mM Tris±HCl pH 7.4, 1.0 mM Na3VO4), then centrifuged to remove
unlysed cell fragments. Ten micrograms of protein from the lysate of each
cell type was then boiled for 10 min with sample buffer (Laemmli, 1970),
and proteins were separated on an 8% SDS±PAGE minigel. One hundred
nanograms per ml PY-20 anti-phosphotyrosine antibody or 250 ng per ml
70 WANG ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
mouse monoclonal antibody speci®cally directed against the
phosphorylated form of EGF-R were used to detect activated EGF-R.
Immunoreactive bands were treated with peroxidase-conjugated goat anti-
mouse antibodies, then detected with an enhanced chemiluminescence kit,
and developed on Kodak X-Omat ®lm at room temperature for 10 s. EGF-
R phosphorylation studies were performed six times.
Total EGF-R was quanti®ed by western blotting using the same
procedure, but the EGF-R was detected with 100 ng per ml mouse
monoclonal anti-EGF-R antibody. Expression studies were carried out
four times.
As a control and to determine if the effects of sialidase could be
overcome by the pharmacologic addition of GM3, cells were treated
overnight with 1% FBS and then incubated either with 50 mM GM3 for
seven different durations (30 min to 72 h) or with six concentrations of
GM3 (1 mM to 200 mM) for 48 h before the determination of EGF-R
expression and phosphorylation as described above. GM3 addition studies
were performed three times.
EGF-R tyrosine kinase activity Tyrosine kinase activity was assayed as
previously described by Idelson and Blout (1958) and modi®ed by Rebbaa
et al (1996). Brie¯y, cells were incubated overnight in serum-free medium,
then treated with 10 nM EGF for 10 min at 37°C. Cells were lyzed in cold
buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 100 mM NaF, 1 mM
MgCl2, 1.5 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢-
tetraacetic acid, 200 mM Na3VO4, and 1% nonidet-40) for 30 min at
4°C. Phosphorylation by the EGF-R tyrosine kinase of its substrate
poly(G.T) 4:1 (Glu to Tyr in a 4:1 molar ratio) was accomplished by
incubating 100 mg protein from the cell lysates with 100 ng EGF, 250 mg
poly(G.T) 4:1, 10 mM ATP, and 10 mCi [g-32P]ATP in phosphorylation
buffer (50 mM HEPES pH 7.4, 5 mM MgCl2, 5 mM MnCl2, 200 mM
Na3VO4,1 mM NaF, 0.1 mM phenylmethylsulfonyl ¯uoride, 10 mg per ml
leupeptin) for 30 min at 30°C. The reaction was stopped by 20%
trichloroacetic acid, and the solution was centrifuged to eliminate
unincorporated radiolabeled ATP. After washing, the membrane
radioactivity in scintillation ¯uid was counted in a Beckman LS 6000
scintillation counter. Tyrosine kinase assays were repeated six times.
Protein-tyrosine phosphatase (PTP) assay Cells at 80% con¯uence
were treated with 10 nM EGF for 10 min as described above. Phosphatase
activity was measured as previously described (Rebbaa et al, 1996) using
anti-PTP1D monoclonal antibody. Phosphatase activity was quanti®ed by
spectrophotometry at optical density 410 nm. Assays were performed six
times.
PI3 kinase activity PI3 kinase activity was assayed four times as
previously described (Kim et al, 1994). The immunoprecipitated PI3 kinase
were prepared as described above for tyrosine kinase, except that PI3 kinase
was immunoprecipitated with anti-PI3 kinase antibody. Chloroform/
methanol (1:1) was added to extract the phosphatidylinositol derivatives
(PIP, PIP2), and the lower phase was applied to a thin-layer
chromatography plate. After incubation in 60:40 (vol/vol) propanol:
0.5 M acetic acid, the plate was exposed to Kodak X-Omat ®lm at ±70°C
and developed.
MAP kinase activity MAP kinase activity assay was performed three
times as previously described (Seger et al, 1994). The samples were prepared
as discussed above for tyrosine kinase assays, except the protein extract was
incubated with anti-MAP kinase antibody. The MAP kinase was
resuspended in reaction buffer containing 10 mg myelin basic protein,
10 mCi [g-32P]ATP, and 10 mM ATP for 20 min at 30°C, then boiled in
Laemmli buffer. Samples were applied to a 12% SDS±PAGE minigel, and
label was visualized on Kodak X-Omat ®lm.
Statistical analysis Results are presented as mean 6 SD of the mean.
Differences between means were analyzed using the paired Student's t test.
p < 0.05 was considered statistically signi®cant. Regression analysis and
Scatchard plots were performed using Statistical Analysis Systems Software
(Cary, NC).
RESULTS
The pharmacologic addition of gangliosides to cultured
SCC12 cells inhibits the binding of EGF to its receptor In
order to investigate the mechanism for the inhibition of
proliferation and EGF-R autophosphorylation by gangliosides,
increasing concentrations of 125I-EGF were incubated with SCC12
cells in the presence of gangliosides of both the ``b'' and the ``a''
synthetic pathways. As shown in the insert of Fig 1, 125I-EGF
binding to SCC12 cells is saturated by 12 nM EGF. Scatchard plots
(Fig 1) show that the number of available EGF-R per cell of
SCC12 cells treated with GM3 and the ``b'' gangliosides GT1b and
GD3 (data not shown for GD3) is signi®cantly decreased in
comparison with untreated cells or cells treated with ``a'' pathway
gangliosides GM1 and GM2 (data not shown for GM2) (Table I).
The Kds of cells treated with GM3 and ``b'' pathway gangliosides
also differed by a factor of 2 (Table I). Displacement testing further
con®rmed the ganglioside-induced decrease in binding of EGF to
its receptor (data not shown).
Figure 1. Gangliosides decrease the binding
of 125I-EGF to its receptor. 104 SCC12 cells
were incubated with or without gangliosides for
48 h, and then treated for 4 h with 125I-EGF with
or without unlabeled EGF. Typical saturation
curves showed receptors saturated by 12 nM 125I-
EGF in both treated and untreated cells, although
the amount of bound 125I-EGF was considerably
less in cells treated with gangliosides GM3 and
GT1b (insert). Scatchard analysis also clearly distin-
guished two treatment groups, with distinctive
curves separating the untreated cells and the
GM1-treated cells from the cells incubated with
GM3 and GT1b. s, SCC12 without ganglioside;
h, SCC12 + GM1; e, SCC12 + GM3; n,
SCC12 + GT1b.
Table I. Effect of gangliosides on the binding parameters of
125I-EGF to SCC12 cellsa
Cell Apparent R-adjusted Number of
type Kd (nM) receptors
per cell
SCC12/no Gang 0.61 0.898 186,620
SCC12/GM1 0.61 0.938 195,695
SCC12/GM3 1.59 0.983 129,430
SCC12/GT1b 1.43 0.993 111,370
pcDNA 0.64 0.974 189,630
SIA S10 0.51 0.963 401,534
SIA S12 0.57 0.996 439,460
aThe binding of 125I-EGF to SCC12 cells at 4°C was carried out as described in
Materials and Methods. Kd and receptor number were determined from a Scatchard
plot of the binding using a Statistical Analysis System (SAS) program.
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Sialidase cDNA transfection increases the expression of cell
sialidase and endogenously depletes keratinocyte
gangliosides To create a keratinocyte model of ganglioside
depletion, we stably transfected into the SCC12 line a cDNA
encoding a sialidase that metabolizes gangliosides. Sixty-two clonal
cell lines transfected with the 1.2 kb Chinese hamster ovary sialidase
cDNA and three vector transfected clonal cell lines (mock
transfectants) were recovered after G418 drug selection and
limiting dilutions. Sialidase activity was measured as an initial
means to verify expression in these 62 sialidase-transfected clones.
Because the product of the transfected sialidase cleaves gangliosides
most actively at neutral pH (Warner et al, 1993), whereas lysosomal
sialidases act optimally at pH 4.0 (Fiorilli et al, 1989), sialidase
activity was measured at both pH 4.0 and pH 6.8. Sialidase activity
was increased 2±3-fold above parental SCC12 cells and mock
transfectants in 20 of the sialidase cDNA transfected clones at
pH 6.8. No clones showed increased activity at pH 4.0. To assure
the validity of the assay further, a speci®c inhibitor of sialidase
activity, 2,3-dehydro-2-deoxy-N-acetylneuraminic acid, was
added to both control and sialidase-transfected cells (Usuki et al,
1988). The inhibitor reduced the level of sialidase activity at pH 6.8
in all cell lines to a basal level of 550±600 relative ¯uorescence
units. Expression of sialidase mRNA was sought by northern assay
in the 20 clones with high sialidase activity. Of these, six clones
showed sialidase mRNA expression that was 8±10-fold higher than
mock-transfected clones and the parental cell line, and sialidase
activity that was 5±6-fold higher. These results resembled the levels
of expression seen by Meuillet et al (1999) after sialidase transfection
of A-431 cells. The high expression of sialidase was maintained for
at least 7 mo after transfection in the six clones that were used for all
further studies: S1, S5, S8, S10, S11, and S12.
Whereas the ganglioside content was not altered in the vector
transfected (pcDNA) cells from the parental SCC12 cells, no
ganglioside was detectable in resorcinol-treated thin-layer chro-
matographic plates of extracted membranes from sialidase-trans-
fected cells (Fig 2a). Doubling the number of cells loaded on to
thin-layer chromatography plates still resulted in no detection of
ganglioside bands in sialidase overexpressors (data not shown).
Increased sialidase activity does not affect glycosylation of
glycoproteins Lectin staining was performed to investigate
whether the sialidase expression depleted the sialylation of
glycoproteins, especially of the EGF-R. No gross difference in
lectin staining was noted; speci®cally, sialidase-expressing cells did
not show a depletion in binding to MAA (a2,3-sialic acid
glycoprotein linkages) or to SNA (a2,6-sialic acid glycoprotein
linkages), or an increase in binding to peanut agglutinin (galactose-
b-1,3-N-acetylgalactosamine core protein remaining after cleavage
of the terminal a2,3-sialic acid residues) (data not shown). Studies
with MAA lectin binding showed three bands, including one in the
vicinity of the 180 kDa EGF-R. To consider further an alteration
in the glycosylation of the EGF-R, the EGF-R was
immunoprecipitated from the parental cells, mock pcDNA cell
clone, and six sialidase positive clones. Whereas this
immunoprecipitated EGF-R was detectable with MAA lectin
staining, no detectable alteration in MAA binding was noted
(Fig 2b). Peanut agglutinin and SNA lectins did not bind to the
immunoprecipitated EGF-R (data not shown).
Addition of GM3 suppresses cell proliferation and EGF-R
tyrosine phosphorylation, whereas depletion of ganglioside
increases cell proliferation, phosphorylation of the EGF-R,
and tyrosine kinase activity, and activation of downstream
signaling factors MAP kinase and PI3 kinase At 5 d culture
with serum-containing medium, a statistically signi®cant difference
(p < 0.05) in the number of cells per well was noted between
Figure 2. Sialidase-speci®c characterization. (a) Sialidase overexpression results in membrane ganglioside depletion. Ganglioside was extracted from
SCC12, mock clone (pcDNA) and six sialidase cDNA transfected positive clones in chloroform/methanol 1:1 (vol/vol) and the resulting aqueous phase
desalted on a C-18 column. The ganglioside of 109 cells from each cell clone was applied for each lane. Gangliosides were extracted with chloroform/
methanol (1:1 vol/vol), and puri®ed with C-18 column. Gangliosides were separated by thin-layer chromatography in chloroform/methanol/0.2% CaCl2
solution (55/45/10, vol/vol/vol), and detected by resorcinol staining. SCC12 cells and the pcDNA-transfected clonal cells both showed the expected
doublet of GM3, and additional bands of 9-O-acetylGD3, GD3, and GT1b. No ganglioside was detected in any of the lanes of sialidase-transfected cells. All
chromatographs from four different preparations were identical. (b) Increased sialidase expression does not affect the glycosylation of proteins. The
glycosylation state of glycoproteins in sialidase overexpressing clones was assessed by staining with DIG-labeled lectins that recognize different sugar moieties.
No difference in staining was detected by lectin binding with MAA, SNA, or peanut agglutinin (not shown). MAA lectin binding studies demonstrated a
band in the vicinity of 170 kDa, the molecular weight of the EGF-R. To ensure that the sialidase does not alter EGF-R sialylation speci®cally, total cell
protein from sialidase cDNA transfected positive clones and controls was immunoprecipitated with anti-EGF-R monoclonal antibody. After
electrophoresing the denatured EGF-R protein in an 8% SDS±PAGE mini-gel, the protein was transferred to nitrocellulose membrane and probed with
5 mg per ml MAA. No change in lectin labeling of immunoprecipitated EGF-R was detected.
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sialidase-expressing clones and control cells (Fig 3a). The addition
of 10 nM EGF (Fig 3b) or 12 nM TGF-a (Fig 3c) to cultures after
serum and growth factor starvation overnight further exaggerated
the difference in proliferation, with a statistically signi®cant
difference seen already by 24 h after plating. Consistently,
sialidase-expressing clones showed a 2±4-fold increase in
autophosphorylation of the EGF-R (Fig 4a). No increased
expression of EGF-R in extracted total cell protein was
detectable by western blot assay (Fig 4b). When concentrations of
GM3 as high as 200 mM were added to cells that overexpressed
sialidase, no suppression of the increased EGF-R phosphorylation
was noted (data not shown). In contrast, GM3 concentrations as
low as 10 mM decreased EGF-R phosphorylation in SCC12 and
mock-transfected cells (Fig 4a). The increased phosphorylation did
not result from decreased EGF-R-related phosphatase activity (data
not shown). Sialidase overexpressors showed a 6±10-fold increase
in tyrosine kinase activity (Fig 4c). Downstream substrates PI3
kinase (Fig 5a) and MAP kinase (Fig 5b), also showed increased
phosphorylation.
Endogenous depletion of ganglioside leads to increased
binding of EGF to sialidase-overexpressing SCC12
cells Given the diminished binding of EGF to its receptor in
the face of pharmacologically increased membrane concentrations
of ganglioside, we hypothesized that endogenously depleted
ganglioside expression would lead to increased EGF-R binding
to ligand. Both Scatchard analysis and displacement assays showed
that ganglioside-depleted SCC12 cells have increased numbers of
available surface receptors without a difference in Kd (Fig 6,
Table I).
DISCUSSION
Gangliosides, sialylated glycosphingolipids of eukaryotic mem-
branes, are thought to affect cell±cell recognition, cell±substratum
interactions, cell growth regulation, differentiation, and oncogenic
transformation (for reviews, Hakomori and Igarashi, 1993; Bremer,
1994). These ganglioside-induced effects result, at least in part,
from growth factor receptor transmembrane modulation. A variety
of techniques, ranging from the pharmacologic addition of puri®ed
gangliosides in vitro, to the addition of ganglioside inhibitors or
metabolizers, to transfection of enzymes that modulate ganglioside
biosynthesis, have been used to alter the content of membrane
gangliosides and address their role in signal transduction. For
example, gangliosides GM3 and GT1b inhibit the growth of
cultured keratinocytes and keratinocyte-derived cells through a
mechanism that involves inhibition of EGF-R tyrosine phosphor-
ylation, whereas ganglioside GM1 has little effect (Bremer et al,
1986; Paller et al, 1993). In contrast, GM1 is a potent inhibitor of
platelet-derived growth factor receptor phosphorylation and
platelet-derived growth factor induced proliferation of 3T3 cells
(Bremer et al, 1984; Yates et al, 1993; Sachinidis et al, 1996). These
variable effects among gangliosides suggest that the carbohydrate
moieties of gangliosides, which distinguish gangliosides from one
another, are likely to be critical for function. The concept of a
crucial part for the carbohydrate moieties of ganglioside is further
supported by the lack of inhibitory effect when asialylated or de-N-
acetylated forms of gangliosides are added to cells (Bremer et al,
1984; Song et al, 1993), or when carbohydrates are depleted by the
glucosyltransferase inhibitor D-threo-1-phenyl-2-decanoylamino-
3-morpholino-1-propanol (PDMP) (Meuillet et al, 2000), by the
glucosylceramide synthase inhibitor D-1-threo-1-phenyl-2-hexa-
decanoylamino-3-pyrrolidino-1-propanol-HCl (PPPP) (Li et al
2000) or by sialidase-induced depletion of GM3 from A-431 cells
(Meuillet et al, 1999).
The mechanism by which gangliosides alter receptor tyrosine
phosphorylation remains unclear. Few studies have addressed the
possibility of alterations in binding of the EGF-R to its ligand.
Whereas Bremer et al (1986) initially showed the inhibition of
proliferation and tyrosine phosphorylation of the EGF-R by
ganglioside GM3, they observed no difference in the saturation
Figure 3. Sialidase cDNA transfection results in increased cell
proliferation. Cells were seeded in 12-well plates in complete medium
and counted daily for 8 d. (a) Increased proliferation in sialidase-positive
cells was detected by 5 d after culture initiation (p < 0.05). Twelve hours
after cells were plated in complete medium, the cells were switched to
serum-free medium overnight, then treated with 10 nM EGF (b), or with
12 nM TGF-a (c). A statistically signi®cant increase in proliferation was
noted in the sialidase-transfected cells within 24 h of incubation with the
EGF. s, SCC12; h, pcDNA; r, S1; m, S5; j, S8; e, S10; n, S12.
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curves of binding of cultured epidermoid cell lines KB or A-431 to
125I-EGF. Using competition displacement assays with sialidase-
transfected A-431 cells that were depleted of GM3, no increase in
binding of 125I-EGF to cells was detected (Meuillet et al, 1999),
despite the resultant increase in EGF-R tyrosine phosphorylation.
The possibility that ganglioside affects EGF-R to ligand binding
was further assessed in the keratinocyte-derived SCC12 cell line,
which more closely resembles normal human keratinocytes than
the A-431 cell line based on cell morphology (Rheinwald, 1982),
number of EGF receptors, ganglioside content with predominantly
GM3, GD3, 9-O-acetyl-GD3, and trace amounts of GT1b, and its
response to exogenously introduced ganglioside (Sung et al, 1998).
By overexpressing into SCC12 cells, a Chinese hamster ovary
sialidase that selectively cleaves gangliosides, we endogenously
modulated ganglioside content, eliminating all detectable ganglio-
side. In contrast to the decrease in EGF binding to the receptor in
cells with excessive membrane GM3, ganglioside-depleted kerati-
nocytes showed increased EGF-R binding to ligand, consistent
with the demonstration of increased proliferation in response to
both EGF and TGF-a (the more important ligand for keratino-
cytes) (Coffey et al, 1987), and increased activation of the EGF-R
and its signal transduction pathway components. Both parental
Figure 4. Ganglioside depletion increases EGF-R autophosphoryla-
tion and tyrosine kinase activity, whereas increased ganglioside
suppresses EGF-R phosphorylation. Ten micrograms cell lysate from
each of sialidase-overexpressing and control clones was electrophoresed on
an 8% SDS±PAGE minigel, and transferred to polyvinylidene di¯uoride
membrane. To detect autophosphorylation of the EGF-R, the membrane
was incubated with 250 ng per ml monoclonal antibody directed
speci®cally against the activated form of EGF-R, and binding was detected
with an enhanced chemiluminescence system. Sialidase overexpression
increased EGF-R autophosphorylation in comparison with controls by 2±
4-fold, as measured by densitometry, whereas addition of GM3 inhibited
EGF-R phosphorylation in control cells (a). Western blot analysis using
anti-EGF-R monoclonal antibody (not activated form) showed no
difference among cell lines in EGF-R expression of extracted total protein
(b). To determine tyrosine kinase activity (c), serum-starved cells were
stimulated with 10 nM EGF, lyzed, and incubated with 100 ng EGF,
250 mg per ml poly(G.T) 4:1, 10 mM ATP and 10 mCi [g-32P]ATP in
phosphorylation buffer for 30 min at 30°C. The amount of [g-32P]-labeled
substrate-poly(G.T) 4:1 was measured in a Beckman LS 6000 scintillation
counter.
Figure 5. Ganglioside depletion increases PI3 kinase and MAP
kinase activity. Cells grown in DMEM/F12 with 10% FBS were serum-
starved, stimulated with 10 nM EGF for 10 min, and lyzed. Five hundred
micrograms of cell lysate was immunoprecipitated by incubation with anti-
PI3 kinase (a) or anti-MAP kinase antibody (b). The puri®ed PI3 kinase was
reacted with its substrate, phosphatidylinositol, and [g-32P]ATP for 30 min
at 30°C. The phosphatidylinositol derivatives (PIP, PIP2) were resolved by
thin layer chromatography, and the radiolabeled material was detected by
autoradiography. The MAP kinase was resuspended in reaction buffer
containing 10 mg myelin basic protein, 10 mCi [g-32P]ATP, and 10 mM
ATP for 20 min at 30°C, then boiled in Laemmli buffer. Samples were
applied to a 12% SDS±PAGE minigel, and label was visualized on Kodak
X-Omat ®lm.
Figure 6. Ganglioside depletion increases the binding of EGF-R
with its ligand EGF. Cells were grown in 96-well Multiscreen ®lter plates
and incubated with 12 nM 125I-EGF for 4 h at 4°C in the presence of
varying amounts of cold EGF as high as 1 mM to detect dissociation as
indicated. Membrane bound radioactivity was counted in a Beckman
LS6000 scintillation counter. s, SCC12; h, pcDNA; r, S1; m, S5; j, S8;
e, S10; d, S11; n, S12.
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SCC12 cells treated with exogenous GM3 and sialidase-transfected
SCC12 cells showed alterations in EGF-R ligand binding, as
opposed to the effects of ganglioside modulation described for A-
431 cells. Although the discrepancy between our data and that of
the previous studies may re¯ect the difference in cell type, our use
of membrane ®lters that obviate the need to strip cells from the
plate may have allowed more ef®cient recovery of radioactive
material. Furthermore, Triton X-100 detergent used in previous
studies has been shown to affect EGF-R function, including the
inhibitory effect of GM3 (Hanai et al, 1988; Igarashi et al, 1990),
suggesting that its use in the assay may also change receptor
orientation.
The alteration in EGF binding at the cell surface may be
explained by a change in the number of active receptors available
on the cell surface or by a change in the binding af®nity of ligand to
the EGF-R. The decrease in binding appeared to be primarily the
result of decreased numbers of available EGF receptors. Although
the Kd also increased 2-fold when cells were treated with GM3,
differences in autophosphorylation were still observed at 10 nM
EGF, well above the EGF binding saturation point. If the decrease
in binding were due primarily to an af®nity difference, this
difference would not be present when at binding saturation.
Furthermore, no difference in Kd was noted in the SCC12 cells
depleted of gangliosides by sialidase transfection, although the
number of available EGF receptors increased by more than 2-fold.
Whereas this alteration in receptor availability for ligand binding
affects EGF-R activation and downstream events, the 2±4-fold
increase in EGF-R phosphorylation and the 6±10-fold increase in
tyrosine kinase activity in ganglioside-depleted SCC12 cells
suggests that postbinding receptor activation may also participate.
The observed change in number of EGF-R per cell may re¯ect
altered receptor synthesis or degradation, or a change in the
number of receptors available for binding. Our western blotting
studies with protein extracted from ganglioside depleted SCC12
cells did not show a detectable increase in the binding of EGF-R
antibody to the protein, despite our demonstration that the density
of detected binding of anti-EGF-R antibody to the cell protein is a
function of loading until 20±40 mg total protein. The clear
difference between detectable EGF-R by western blotting in the
range of loaded membrane protein of 5±20 mg suggests that a 2.25-
fold increase in receptor number should have been detected when
10 mg was applied, and provides evidence that the synthesis of EGF-
R was not affected by ganglioside depletion. Although an increased
binding af®nity could also explain the lack of detectable alteration
in EGF-R expression, more likely the western blotting assay results
emphasize the importance of the structural orientation of GM3 and
other gangliosides in relation to the EGF-R in allowing accessibility
of the EGF-R for binding, as intact cells were used for Scatchard
assays in contrast to extracted receptor protein in the western assays.
A direct interaction between GM3 and the EGF-R has been
suggested by Hanai et al (1988) who previously demonstrated the
coimmunoprecipitation of GM3 with the EGF-R, and by the
preferential binding of the EGF-R to GM3-coated plates (Yednak
and Bremer, 1994). Taken together, our new data on ganglioside
inhibition of ligand binding and the direct interaction studies
provide a theoretical model of direct contact of GM3 or other ``b''
pathway gangliosides with the EGF-R, which blocks the
availability of receptor binding to its EGF or TGF-a ligand.
Clearly, the observed effect of gangliosides on binding of the
EGF-R to its ligands occurred under controlled culture conditions;
however, the strong correlation of binding alterations with
functional changes in vitro suggests physiologic relevance. In view
of the importance of growth factor receptors in the proliferation of
cancer cells, modulators of growth factor activity have recently
received attention as novel anti-neoplastic agents. The demonstra-
tion that gangliosides decrease the binding of ligand to the EGF
receptor and thereby diminish cell proliferation further supports the
use of modulation of membrane ganglioside content, whether
through gene activation or pharmacologic addition, for treating
neoplastic and other hyperproliferative disorders.
We acknowledge Tina Chang, M.S. for her assistance with statistical analysis. This
study was supported by NIH-R01 AR44619.
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